Cue Biopharma, Inc. — Director's Dealing 2021

Oct 6, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cue Biopharma, Inc. (CUE)
CIK: 0001645460
Period of Report: 2021-08-23

Reporting Person: Millar Kerri-Ann (CHIEF FINANCIAL OFFICER)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-23	Common Stock	M	6667	$0.00	Acquired	12433	Direct
2021-08-23	Common Stock	F	1961	$0.00	Disposed	10472	Direct
2021-10-01	Common Stock	M	1251	$7.50	Acquired	11723	Direct
2021-10-01	Common Stock	S	1251	$14.2149	Disposed	10472	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-08-23	Restricted Stock Units	$	M	6667	Disposed		Common Stock (6667)	Direct
2021-10-01	Stock Option (right to buy)	$7.50	M	1251	Disposed	2024-12-27	Common Stock (1251)	Direct

Footnotes

F1: Represents shares of common stock received upon vesting of a restricted stock unit award.

F2: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2021.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.01 to $14.46, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (3) to this Form 4.

F4: Each restricted stock unit award represents a contingent right to receive one share of common stock.

F5: Represents a restricted stock unit award granted on August 21, 2020. The restricted stock units vest in three equal annual installments beginning on August 21, 2020.

F6: The option vests in eight equal semi-annual installments beginning March 25, 2018.